CO6321229A2 - Derivados de fenil benzamida utiles en el tratamiento de cancer y psoriasis - Google Patents

Derivados de fenil benzamida utiles en el tratamiento de cancer y psoriasis

Info

Publication number
CO6321229A2
CO6321229A2 CO10023922A CO10023922A CO6321229A2 CO 6321229 A2 CO6321229 A2 CO 6321229A2 CO 10023922 A CO10023922 A CO 10023922A CO 10023922 A CO10023922 A CO 10023922A CO 6321229 A2 CO6321229 A2 CO 6321229A2
Authority
CO
Colombia
Prior art keywords
alkyl
group
bond
cycloalkyl
alkoxy
Prior art date
Application number
CO10023922A
Other languages
English (en)
Inventor
Leslie Dakin
Benjamin Fauber
Alexander Hird
James Janetka
Daniel John Russell
Qibin Su
Bin Yang
Xiaolan Zheng
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39967396&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6321229(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO6321229A2 publication Critical patent/CO6321229A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

1.- Un compuesto de fórmula lAen donde- - - - representa un enlace simple o doble;- - - - representa un enlace simple, un doble enlace, un triple enlace o cuando X o Y es un enlace directo - - - - representa la ausencia de un enlace;R1, R2, R3 y R4 se seleccionan cada uno independientemente del grupo que consiste en hidrógeno, alcoxiC1-6, alcoxiC1-6alquiloC1-6, alquiloC1-6, aminoalquiloC1-6, cicloalquiloC3-8, ciano, haloalquiloC1-6, halógeno, hidroxi, sulfonilo, sulfuro y tio,con la condición de que R2 o R3 es Z;cada W se selecciona independientemente del grupo que consiste en CR10, NR10, N, O y S, donde R10 se selecciona del grupo que consiste en hidrógeno, alcoxiC1-6, alcoxiC1-6alquiloC1-6, alcoxiC1-6carbonilo, alquiloC1-6, amidino, amido, amino, arilo, carboxamido, ciano, haloalquiloC1-6, halógeno, heterociclilalquiloC1-6, cicloalquiloC3-6, hidroxi, hidroxialquiloC1-6, nitro, sulfuro, sulfonamido y sulfonilo, odos átomos W adyacentes pueden tomarse junto con sus sustituyentes R10 para formar un segundo anillo fusionado, en donde el segundo anillo se selecciona del grupo que consiste en arilo, cicloalquiloC3-8, un heteroarilo de 5 ó 6 miembros y un heterociclilo de 5 ó 6 miembros;q es 0 ó 1, dondesi q es 0 y dos átomos W adyacentes tomados junto con sus sustituyentes R10 forman un biciclo seleccionado del grupo que consiste en bencimidazolilo, benzoxazolilo, benzotiazolilo y oxazolopiridilo, entonces, por lo menos un A es N,si q es 1, dos W son N, y dos átomos W adyacentes tomados junto con sus sustituyentes R10 forman un quinoxalinilo, entonces, por lo menos un A es N, y ...
CO10023922A 2007-08-31 2010-03-01 Derivados de fenil benzamida utiles en el tratamiento de cancer y psoriasis CO6321229A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96936407P 2007-08-31 2007-08-31
US3665808P 2008-03-14 2008-03-14

Publications (1)

Publication Number Publication Date
CO6321229A2 true CO6321229A2 (es) 2011-09-20

Family

ID=39967396

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10023922A CO6321229A2 (es) 2007-08-31 2010-03-01 Derivados de fenil benzamida utiles en el tratamiento de cancer y psoriasis

Country Status (23)

Country Link
US (1) US20100311748A1 (es)
EP (1) EP2188255A1 (es)
JP (1) JP2010537967A (es)
KR (1) KR20100047901A (es)
CN (1) CN101835752A (es)
AR (1) AR068140A1 (es)
AU (1) AU2008291921A1 (es)
BR (1) BRPI0816050A2 (es)
CA (1) CA2696767A1 (es)
CL (1) CL2008002560A1 (es)
CO (1) CO6321229A2 (es)
CR (1) CR11299A (es)
DO (1) DOP2010000067A (es)
EA (1) EA201000365A1 (es)
EC (1) ECSP10010035A (es)
MX (1) MX2010002353A (es)
NI (1) NI201000033A (es)
PE (1) PE20090641A1 (es)
SV (1) SV2010003497A (es)
TW (1) TW200918521A (es)
UY (1) UY31314A1 (es)
WO (1) WO2009027746A1 (es)
ZA (1) ZA201001194B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8129530B2 (en) 2007-08-31 2012-03-06 H. Lundbeck A/S Catecholamine derivatives and prodrugs thereof
CA2707492A1 (en) * 2007-12-13 2009-06-18 Amgen Inc. Gamma secretase modulators
US20090281089A1 (en) * 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
MX2010014171A (es) * 2008-06-19 2011-07-04 Xcovery Holding Co Llc Compuestos de piridazin-carboxamida sustituida como compuestos inhibidores de cinasa.
EP2330894B8 (en) 2008-09-03 2017-04-19 BioMarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors
WO2011085128A1 (en) * 2010-01-07 2011-07-14 Selexagen Therapeutics, Inc. Hedgehog inhibitors
WO2011085261A1 (en) * 2010-01-08 2011-07-14 Selexagen Therapeutics, Inc. Hedgehog inhibitors
WO2011095807A1 (en) 2010-02-07 2011-08-11 Astrazeneca Ab Combinations of mek and hh inhibitors
JP5769348B2 (ja) * 2010-03-22 2015-08-26 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー １−（２−フェノキシメチルヘテロアリール）ピペリジン化合物および１−（２−フェノキシメチルヘテロアリール）ピペラジン化合物
CA2828524C (en) 2011-02-28 2020-01-07 Repligen Corporation Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
ES2748656T3 (es) * 2011-10-28 2020-03-17 Inhibitaxin Ltd Derivados de piridazina útiles en terapia
PT2797416T (pt) 2011-12-28 2017-10-23 Global Blood Therapeutics Inc Compostos de benzaldeído substituído e métodos para a sua utilização no aumento da oxigenação de tecidos
ES2790358T3 (es) 2011-12-28 2020-10-27 Global Blood Therapeutics Inc Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular
CN103570625A (zh) * 2012-07-19 2014-02-12 南京英派药业有限公司 N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
JP6503338B2 (ja) 2013-03-15 2019-04-17 バイオマリン ファーマシューティカル インコーポレイテッド Ｈｄａｃ阻害剤
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
MY180206A (en) 2013-03-15 2020-11-25 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
CN105073728A (zh) 2013-03-15 2015-11-18 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AP2015008718A0 (en) 2013-03-15 2015-09-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
DK3102208T3 (da) 2014-02-07 2021-03-08 Global Blood Therapeutics Inc Krystallinsk polymorf af den frie base af 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyd
JP6769963B2 (ja) 2014-08-29 2020-10-14 ティエエッセ ファルマ ソチエタ レスポンサビリタ リミタータ α−アミノ−β−カルボキシムコン酸セミアルデヒド脱炭酸酵素の阻害剤
JOP20180072A1 (ar) 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين
CN104529905B (zh) * 2014-12-09 2017-10-31 沈阳药科大学 N‑3‑苯并咪唑酰双胺类衍生物及其制备方法与应用
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
MX2017015681A (es) 2015-06-04 2018-09-11 Pellepharm Inc Formulaciones topicas para suministrar compuestos inhibidores de hedgehog y uso de los mismos.
MA43373A (fr) 2015-12-04 2018-10-10 Global Blood Therapeutics Inc Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde
AR108435A1 (es) 2016-05-12 2018-08-22 Global Blood Therapeutics Inc Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
EP3568395A1 (de) 2017-01-10 2019-11-20 Bayer Aktiengesellschaft Heterocyclen-derivate als schädlingsbekämpfungsmittel
TW201837036A (zh) 2017-01-10 2018-10-16 德商拜耳廠股份有限公司 作為除害劑之雜環衍生物（一）
EP3601250A4 (en) * 2017-03-27 2020-11-25 Pharmakea, Inc. APOPTOSIS SIGNAL REGULATION KINASE 1 (ASK 1) INHIBITOR COMPOUNDS
WO2020072377A1 (en) 2018-10-01 2020-04-09 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease
CN110759831B (zh) * 2019-10-16 2022-09-27 浙江金伯士药业有限公司 制备常山酮中间体2-氨基-4-溴-5-氯苯甲酸方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10306250A1 (de) * 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2767153A1 (en) * 2003-02-20 2004-09-02 Encysive Pharmaceuticals Inc. Phenylenediamine urotensin-ii receptor antagonists and ccr-9 antagonists
EA201890903A9 (ru) * 2004-09-02 2021-11-10 Дженентек, Инк. Соединения пиридиловых ингибиторов передачи сигналов белком hedgehog, способ их получения, композиция и способы лечения рака и ингибирований ангиогенеза и сигнального пути hedgehog в клетках на их основе
ES2537898T3 (es) * 2005-10-25 2015-06-15 Shionogi & Co., Ltd. Derivados de aminotiazolidina y aminotetrahidrotiazepina como inhibidores de BACE 1

Also Published As

Publication number Publication date
BRPI0816050A2 (pt) 2017-05-02
DOP2010000067A (es) 2010-05-31
JP2010537967A (ja) 2010-12-09
EA201000365A1 (ru) 2010-10-29
AU2008291921A1 (en) 2009-03-05
EP2188255A1 (en) 2010-05-26
CL2008002560A1 (es) 2009-07-17
CN101835752A (zh) 2010-09-15
NI201000033A (es) 2010-12-07
ECSP10010035A (es) 2010-04-30
SV2010003497A (es) 2010-07-06
US20100311748A1 (en) 2010-12-09
AR068140A1 (es) 2009-11-04
MX2010002353A (es) 2010-05-03
KR20100047901A (ko) 2010-05-10
UY31314A1 (es) 2009-03-31
CR11299A (es) 2010-05-28
TW200918521A (en) 2009-05-01
WO2009027746A1 (en) 2009-03-05
CA2696767A1 (en) 2009-03-05
PE20090641A1 (es) 2009-06-26
ZA201001194B (en) 2011-12-28

Similar Documents

Publication Publication Date Title
CO6321229A2 (es) Derivados de fenil benzamida utiles en el tratamiento de cancer y psoriasis
CO6190626A2 (es) Compuestos y composiciones como inhibidores de proteasa activadora de canal
CO6140033A2 (es) Amino-imidazoles y su uso como medicamento para tratar discapacidad coognotiva enfermedad de alzheimer neurodegeneracion y demencia
AR072936A1 (es) Derivados piridazin y pirimidin condensados con heterociclos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos como agentes anticancer.
CR11220A (es) Derivados de pirimidina 934
AR058124A1 (es) Derivados de ftalazinona como inhibidores de parp-1
MX2009006878A (es) Derivados indolicos con anillo unido en las posiciones 4,5 para tratar o prevenir infecciones virales por virus de la hepatitis c e infecciones virales relacionadas.
PE20130155A1 (es) Derivados de ariletinilo
UY30670A1 (es) Nuevos compuestos de pirazolina, composiciones conteniéndolos y aplicaciones.
AR054365A1 (es) Derivados de heteroaril benzamidas, composiciones farmaceuticas que los contienen, usos en enfermedades mediadas por glucoquinasasy metodo de preparacion de los mismos.
CO6321239A2 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
PA8783601A1 (es) Derivados de piperidina/piperazina
ECSP099324A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
CO5060482A1 (es) Derivados terapeuticos de biarilo
ES2297727T3 (es) Derivados de octahidropirrolo(3,4-c)pirrol y su empleo como agentes antiviricos.
AR049894A1 (es) Derivados de prolina y sus usos como inhibodores de la enzima dipeptidilpeptidasa-iv
AR048055A1 (es) Derivados de pirimidina como inhibidores de dipeptidil peptidasa
CO6140060A2 (es) Derivados de aminocicloalquil 1,2,4-triazol como moduladores de mglur5
CY1117862T1 (el) Ετεροκυκλικες ενωσεις βενζοδιοξολιου ή βενζοδιοξεπινης ως αναστολεις φωσφοδιεστερασης
ATE451910T1 (de) Verwendung von benzotriazolderivaten zur photostabilisierung
NI201000039A (es) Derivados de quinazolinadiona, su preparación y sus aplicaciones terapéuticas.
CO6180439A2 (es) Derivados de quinuclidinol como antagonistas de receptores muscarinicos
PE20181885A1 (es) Derivados de indolin-2-ona
PE20140968A1 (es) Derivados de benzamida sustituida
UY32801A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen

Legal Events

Date Code Title Description
FA Application withdrawn